CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Trial of Bevacizumab, Radiation Therapy and Temodar Followed by Bevacizumab and Temodar With Continuation of Bevacizumab Beyond Progression (BBP-Bevacizumab Beyond Progression)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01740258
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:51.004923+00:00
Published At: 2020-12-02T00:00:00+00:00
Record Updated At: 2021-01-26
Results Posted At: 2020-12-02
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Malignant Glioma", "Grade 4 Malignant Glioma", "Glioblastoma", "Gliosarcoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2021-01-26"
protocolSection.identificationModule.nctId: "NCT01740258"
protocolSection.identificationModule.officialTitle: "Phase II Trial of Bevacizumab, Radiation Therapy and Temodar Followed by Bevacizumab and Temodar With Continuation of Bevacizumab Beyond Progression (BBP-Bevacizumab Beyond Progression)"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2020-12-02"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.